2. Search Result
Search Result
Results for "

OPM2

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

2

Natural
Products

1

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-50905
    Dovitinib
    10+ Cited Publications

    CHIR-258; TKI258

    		 FLT3 c-Kit FGFR VEGFR PDGFR c-Fms Cancer
    Dovitinib (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC50s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively. Dovitinib has potent antitumor activity [2].
    Dovitinib
  • HY-111451
    Tuvusertib
    1 Publications Verification

    M1774; ATR inhibitor 1

    		 ATM/ATR Cancer
    Tuvusertib (M1774; ATR inhibitor 1) is a selective and orally active ATR inhibitor extracted from patent WO2015187451A1, compound I-l, with a Ki value below 1 μΜ .
    Tuvusertib
  • HY-128360
    dMCL1-2

    		PROTACs Bcl-2 Family Apoptosis Caspase Cancer
    dMCL1-2 is a potent, selective MCL1 PROTAC degrader based on a Cereblon ligand, with a KD value of 30 nM for binding to MCL1. dMCL1-2 induces ubiquitination and degradation of MCL1. dMCL1-2 degrades MCL1, cleaves Caspase-3, and induces Apoptosis. dMCL1-2 can be used in research related to multiple myeloma .
    dMCL1-2
  • HY-N8309
    Luteolin-4'-O-glucoside

    		Interleukin Related Inflammation/Immunology Cancer
    Luteolin-4'-O-glucoside is an IL-5 inhibitor with an IC50 of 3.7 μM. Luteolin-4'-O-glucoside resists hyperuricemia and acute gouty arthritis activity. Luteolin-4'-O-glucoside shows anticancer activity [2] .
    Luteolin-4'-O-glucoside
  • HY-124858
    SC99

    		STAT JAK Apoptosis Cardiovascular Disease Cancer
    SC99 is an orally active, selective STAT3 inhibitor targeting JAK2-STAT3 pathway. SC99 docks into the ATP-binding pocket of JAK2. SC99 inhibits phosphorylation of JAK2 and STAT3 with no effects on the other kinases associated with STAT3 signaling. SC99 inhibits platelet activation, aggregation and displays potent anti-myeloma, anti-thrombotic activities [2] .
    SC99
  • HY-133015
    Mcl-1 inhibitor 3

    		Bcl-2 Family Cancer
    Mcl-1 inhibitor 3 (compound 1) is a highly potent and orally activate macrocyclic Mcl-1 inhibitor (Ki= 0.061 nM; IC50=19 nM in an OPM-2 cell viability assay). Mcl-1 inhibitor 3 shows good pharmacokinetic properties and excellent in vivo efficacy without toxicity .
    .
    Mcl-1 inhibitor 3
  • HY-146445
    P300 bromodomain-IN-1

    		Epigenetic Reader Domain Histone Acetyltransferase Cancer
    P300 bromodomain-IN-1 (Compoun 1u) is a potent p300 (EP300) bromodomain inhibitor with an IC50 of 49 nM. P300 bromodomain-IN-1 suppresses the expression of c-Myc and induces G1/G0 phase arrest and apoptosis in OPM-2 cells .
    P300 bromodomain-IN-1
  • HY-50905R
    Dovitinib (Standard)

    CHIR-258 (Standard); TKI258 (Standard)

    		 FLT3 c-Kit FGFR VEGFR PDGFR c-Fms Reference Standards Cancer
    Dovitinib (Standard) is the analytical standard of Dovitinib. This product is intended for research and analytical applications. Dovitinib (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC50s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively. Dovitinib has potent antitumor activity [2].
    Dovitinib (Standard)
  • HY-180804
    CZL-077

    		Epigenetic Reader Domain Cancer
    CZL-077 is a potent, selective, and orally active p300/CBP bromodomain (BRD) inhibitor (p300 IC50 = 0.034 μM, CBP IC50 = 0.052 μM) exhibiting high selectivity over the BRDs of BET proteins (BRD2/3/4). CZL-077 inhibits cell growth with IC50 values of 0.024 μM and 5.6 μM in OPM-2 and 22RV1 cells, respectively. CZL-077 shows antitumor efficacy in OPM-2 and 22RV1 xenograft mouse models. CZL-077 can be used for multiple myeloma and prostate cancer research .
    CZL-077
  • HY-N8309R
    Luteolin-4'-O-glucoside (Standard)

    		Reference Standards Interleukin Related Inflammation/Immunology Cancer
    Luteolin-4'-O-glucoside (Standard) is the analytical standard of Luteolin-4'-O-glucoside. This product is intended for research and analytical applications. Luteolin-4'-O-glucoside is an IL-5 inhibitor with an IC50 of 3.7 μM. Luteolin-4'-O-glucoside resists hyperuricemia and acute gouty arthritis activity. Luteolin-4'-O-glucoside shows anticancer activity [2] .
    Luteolin-4'-O-glucoside (Standard)
  • HY-180177
    PROTAC BLIMP-1 degrader-1

    		PROTACs Cancer
    PROTAC BLIMP-1 degrader-1 (Compound 49) is a PROTAC-based BLIMP-1 degrader. PROTAC BLIMP-1 degrader-1 promotes the ubiquitination and degradation of BLIMP-1 and can be used in research on myeloproliferative tumors .
    PROTAC BLIMP-1 degrader-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: